Rahul Aggarwal
13
2
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.8%
4 terminated/withdrawn out of 13 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Role: lead
64Cu-GRIP B in Patients With Advanced Malignancies
Role: lead
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Role: lead
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Role: lead
Imaging of Solid Tumors Using 18F-TRX
Role: lead
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
Role: lead
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Role: lead
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Role: lead
Gallium-68 Citrate PET Used in Prostate Cancer
Role: lead
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
Role: lead
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
Role: lead
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
Role: lead
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
Role: lead
All 13 trials loaded